Varseta-M Phase I CRC data, response rates, safety and registrational trial plans for 2027—read key insights now.
14m
GNQ Insilico Inc. to go Public Through Business Combination With IB Acquisition Corp. (NASDAQ: IBAC)
GNQ Insilico Inc. ("GNQ" or the "Company"), a corporation formed under the federal laws of Canada, and IB Acquisition Corp. (Nasdaq: ...
Obexelimab marketing applications for the treatment of IgG4-RD expected to be submitted to the FDA in Q2 2026 and the EMA in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results